LVGN6051
LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma.
Overview
LVGN6051 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Lyvgen Biopharma Holdings Limited, in head and neck squamous cell carcinoma. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody, as described in the registry record.
1.LVGN6051 binds its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"LVGN6051" OR ABSTRACT:"LVGN6051") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LVGN6051, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentAdavosertib
Shares the tags pipeline, registry-only.
- TreatmentAlisertib
Shares the tags pipeline, registry-only.
- TreatmentAMO959
Shares the tags pipeline, registry-only.
- TreatmentAMT-116
Shares the tags pipeline, registry-only.
- TreatmentARD103
Shares the tags pipeline, registry-only.
- TreatmentAU-007
Shares the tags pipeline, registry-only.
- TreatmentAVZO-023
Shares the tags pipeline, registry-only.
- TreatmentAZD0120
Shares the tags pipeline, registry-only.